99m锝-二乙三胺五醋酸-表面活性剂吸入用于成人呼吸窘迫综合征（ARDS）：一种新的诊断治疗工具。

99mTc-DTPA-surfactant inhalation in adult respiratory distress syndrome (ARDS): a new diagnostic-therapeutic tool.

作者信息

Todisco T, Cosmi E, Dottorini M, Baglioni S, Eslami A, Fedeli L, Palumbo R

机构信息

University of Perugia, Perugia, Italy.

出版信息

J Aerosol Med. 1992 Summer;5(2):113-22. doi: 10.1089/jam.1992.5.113.

DOI:10.1089/jam.1992.5.113

PMID:10147686

Abstract

ARDS is a life-threatening pulmonary disease with a rapidly progressive decline due mainly to multi-organ failure. Death occurs in 50-75% of ARDS cases. The diagnosis and therapy should start in the first six days of this fatal disease when mortality is at its lowest level. The 99mTc-DTPA-measured pulmonary alveolar epithelial permeability (PAEP) is strikingly increased in ARDS even in comparison to heavy smokers. Furthermore, surfactant inhalation has been shown to be of therapeutic value. In five ARDS patients with increased PAEP (T0.5 = 12% pred.) 20 mg/kg of aerosolized surfactant determined a dramatic improvement in blood gases and PAEP (51.8% pred.) No patient remained dependent on ventilatory treatment.

摘要

急性呼吸窘迫综合征（ARDS）是一种危及生命的肺部疾病，主要由于多器官功能衰竭导致病情迅速进展恶化。ARDS患者的死亡率为50%-75%。对于这种致命疾病，诊断和治疗应在发病的头六天内开始，此时死亡率处于最低水平。与重度吸烟者相比，ARDS患者经99m锝-二乙三胺五乙酸（99mTc-DTPA）测定的肺泡上皮通透性（PAEP）显著增加。此外，吸入表面活性剂已被证明具有治疗价值。在5例PAEP升高的ARDS患者中（T0.5=预计值的12%），雾化吸入20mg/kg表面活性剂后，血气和PAEP显著改善（51.8%预计值），所有患者均无需依赖机械通气治疗。